Lexaria Bioscience Stock
Lexaria Bioscience Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Richard C. Christopher
- Employees
- 7
- Market cap
- $5 M
- IPO
- 12/01/2021
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown…
Lexaria Bioscience stock: price history
1D
-4.3%
1W
-13.9%
1M
-7.7%
6M
-81.5%
YTD
-69.1%
1Y
-76.9%
2Y
-93.4%
5Y
-97.2%
10Y
–
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~26% weaker price swings than usual
Ask the agents about Lexaria Bioscience
Analyst assessment of Lexaria Bioscience
PRICE TARGET LOW
US$1.50
CONSENSUS
US$1.50
MEDIAN
US$1.50
PRICE TARGET HIGH
US$1.50
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 26/12/2025
Lexaria Bioscience stock metrics
P/E
-0.54
P/B
1
EV/EBITDA
-0.17
RETURN ON EQUITY
-42.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
31/05/2026
Free float & liquidity
FREE FLOAT
97.0%
FLOAT SHARES
1,602,575
AVG. DAILY VOLUME (30D)
90,129
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Lexaria Bioscience stock
What does Lexaria Bioscience do?
Lexaria Bioscience Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Richard C. Christopher, the company employs around 7 people.
The IPO was on 12/01/2021; the stock trades on NASDAQ under the ticker LEXX.
What do analysts say about Lexaria Bioscience stock?
2 analysts rate the stock, the consensus is Buy (as of 26/12/2025).
The average price target is US$1.50, ranging from US$1.50 to US$1.50, with a median of US$1.50.
This is an external assessment, not a statement by Market Jury.
When does Lexaria Bioscience report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly -26% stronger than usual.
Does Lexaria Bioscience pay a dividend?
No, Lexaria Bioscience currently does not pay a dividend.
Which stocks are comparable to Lexaria Bioscience?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Lexaria Bioscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lexaria Bioscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.